Possible Legislation Regarding ESA Administration On The Horizon
Executive Summary
A recent report from the HHS Office of Inspector General regarding erythropoiesis-stimulating agent administration to patients with chronic kidney failure could be laying the foundation for legislative action in the coming year, a staffer for House Ways and Means Health Subcommittee Chairman Pete Stark, D-Calif., said
You may also be interested in...
Access To ESRD Drugs Under Bundled Medicare Payments Concerns GAO
The Government Accountability Office is issuing a cautionary note that Medicare's upcoming prospective payment system for end-stage renal disease might impair access to drugs for some demographic groups
Access To ESRD Drugs Under Bundled Medicare Payments Concerns GAO
The Government Accountability Office is issuing a cautionary note that Medicare's upcoming prospective payment system for end-stage renal disease might impair access to drugs for some demographic groups
CMS Defends Oral ESRD Drug Inclusion In Proposed Bundling Rule
In anticipation of objections to its proposal to include oral end-stage renal disease drugs currently covered under Medicare Part D in bundled payments for ESRD services, CMS offered an extensive justification for the action